167 related articles for article (PubMed ID: 9667653)
1. Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.
Santala M; Risteli J; Risteli L; Puistola U; Kacinski BM; Stanley ER; Kauppila A
Br J Cancer; 1998 Jun; 77(11):1825-31. PubMed ID: 9667653
[TBL] [Abstract][Full Text] [Related]
2. Application of markers of collagen metabolism in serum and synovial fluid for assessment of disease process in patients with rheumatoid arthritis.
Hakala M; Aman S; Luukkainen R; Risteli L; Kauppi M; Nieminen P; Risteli J
Ann Rheum Dis; 1995 Nov; 54(11):886-90. PubMed ID: 7492237
[TBL] [Abstract][Full Text] [Related]
3. Collagen-related markers of bone turnover reflect the severity of liver fibrosis in patients with primary biliary cirrhosis.
Guañabens N; Parés A; Alvarez L; Martínez de Osaba MJ; Monegal A; Peris P; Ballesta AM; Rodés J
J Bone Miner Res; 1998 Apr; 13(4):731-8. PubMed ID: 9580479
[TBL] [Abstract][Full Text] [Related]
4. Assay for cross-linked carboxyterminal telopeptide of type I collagen (ICTP) unlike CrossLaps assay reflects increased pathological degradation of type I collagen in rheumatoid arthritis.
Sassi ML; Aman S; Hakala M; Luukkainen R; Risteli J
Clin Chem Lab Med; 2003 Aug; 41(8):1038-44. PubMed ID: 12964811
[TBL] [Abstract][Full Text] [Related]
5. Markers of type I and III collagen turnover as indicators of growth velocity in very low birth weight infants.
Kajantie E; Dunkel L; Risteli J; Pohjavuori M; Andersson S
J Clin Endocrinol Metab; 2001 Sep; 86(9):4299-306. PubMed ID: 11549665
[TBL] [Abstract][Full Text] [Related]
6. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients.
Ebert W; Muley T; Herb KP; Schmidt-Gayk H
Anticancer Res; 2004; 24(5B):3193-201. PubMed ID: 15510610
[TBL] [Abstract][Full Text] [Related]
7. Type I and III collagen metabolites as predictors of clinical outcome in epithelial ovarian cancer.
Santala M; Simojoki M; Risteli J; Risteli L; Kauppila A
Clin Cancer Res; 1999 Dec; 5(12):4091-6. PubMed ID: 10632345
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum ICTP concentrations reflect poor prognosis in patients with ovarian carcinoma.
Santala M; Risteli L; Puistola U; Risteli J; Kauppila A
Ann Med; 1995 Feb; 27(1):57-61. PubMed ID: 7742000
[TBL] [Abstract][Full Text] [Related]
9. Progressive ovarian carcinoma induces synthesis of type I and type III procollagens in the tumor tissue and peritoneal cavity.
Zhu GG; Risteli J; Puistola U; Kauppila A; Risteli L
Cancer Res; 1993 Oct; 53(20):5028-32. PubMed ID: 8402695
[TBL] [Abstract][Full Text] [Related]
10. Differential processing of type I and type III procollagens in the tumour cysts and peritoneal ascitic fluid of patients with benign and malignant ovarian tumours.
Zhu GG; Melkko J; Risteli J; Kauppila A; Risteli L
Clin Chim Acta; 1994 Sep; 229(1-2):87-97. PubMed ID: 7988058
[TBL] [Abstract][Full Text] [Related]
11. Serum concentrations of type I collagen carboxyterminal telopeptide (ICTP) and type I procollagen carboxy-and aminoterminal propeptides (PICP, PINP) as markers of metastatic bone disease in breast cancer.
Tähtelä R; Thölix E
Anticancer Res; 1996; 16(4B):2289-93. PubMed ID: 8694558
[TBL] [Abstract][Full Text] [Related]
12. Discrepant expression of carboxy- and aminoterminal propeptides of type I procollagen predicts poor clinical outcome in epithelial ovarian cancer.
Simojoki M; Santala M; Risteli J; Kauppila A
Gynecol Oncol; 2003 Mar; 88(3):358-62. PubMed ID: 12648587
[TBL] [Abstract][Full Text] [Related]
13. Type I collagen metabolites as tumor markers in patients with lung carcinoma.
Kobayashi T; Gabazza EC; Taguchi O; Risteli J; Risteli L; Kobayashi H; Yasui H; Yuda H; Sakai T; Kaneda M; Adachi Y
Cancer; 1999 May; 85(9):1951-7. PubMed ID: 10223235
[TBL] [Abstract][Full Text] [Related]
14. Organization of type III collagen in benign and malignant ovarian tumors. An immunohistochemical study.
Zhu GG; Stenbäck F; Risteli L; Risteli J; Kauppila A
Cancer; 1993 Sep; 72(5):1679-84. PubMed ID: 8348501
[TBL] [Abstract][Full Text] [Related]
15. Seromarkers of collagen I and III metabolism in active Crohn's disease. Relation to disease activity and response to therapy.
Kjeldsen J; Schaffalitzky de Muckadell OB; Junker P
Gut; 1995 Dec; 37(6):805-10. PubMed ID: 8537052
[TBL] [Abstract][Full Text] [Related]
16. Low synthesis rate of type I procollagen is normalized during active back rehabilitation.
Hupli M; Hurri H; Luoto S; Risteli L; Vanharanta H; Risteli J
Spine (Phila Pa 1976); 1997 Apr; 22(8):850-4. PubMed ID: 9127916
[TBL] [Abstract][Full Text] [Related]
17. Radiation-induced changes in skin type I and III collagen synthesis during and after conventionally fractionated radiotherapy.
Keskikuru R; Jukkola A; Nuutinen J; Kataja V; Risteli J; Autio P; Lahtinen T
Radiother Oncol; 2004 Mar; 70(3):243-8. PubMed ID: 15064008
[TBL] [Abstract][Full Text] [Related]
18. The use of serologic markers for collagen synthesis and degradation in systemic sclerosis.
Heickendorff L; Zachariae H; Bjerring P; Halkier-Sørensen L; Søndergaard K
J Am Acad Dermatol; 1995 Apr; 32(4):584-8. PubMed ID: 7896946
[TBL] [Abstract][Full Text] [Related]
19. Perinatal collagen turnover markers in intrauterine growth restriction.
Gourgiotis D; Briana DD; Georgiadis A; Boutsikou M; Baka S; Marmarinos A; Hassiakos D; Malamitsi-Puchner A
J Matern Fetal Neonatal Med; 2012 Sep; 25(9):1719-22. PubMed ID: 22339296
[TBL] [Abstract][Full Text] [Related]
20. Markers of type I and type III collagen turnover, insulin-like growth factors, and their binding proteins in cord plasma of small premature infants: relationships with fetal growth, gestational age, preeclampsia, and antenatal glucocorticoid treatment.
Kajantie E; Hytinantti T; Koistinen R; Risteli J; Rutanen EM; Seppälä M; Andersson S
Pediatr Res; 2001 Apr; 49(4):481-9. PubMed ID: 11264430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
